Lung cancer [NEW TOPIC PAGE]

Genomics & Health Impact Scan Database|Search|PHGKB

Publication
IASLC Statement Paper: Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC). Rolfo Christian et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2018 Jun Similar articles in PubMed
Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Targeted Therapy. Copur Mehmet Sitki et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018 May JCO2018788240 Similar articles in PubMed
Evidence-based best practices for EGFR T790M testing in lung cancer in Canada. Stockley T et al. Current oncology (Toronto, Ont.) 2018 Apr 25(2) 163-169 Similar articles in PubMed
Standardizing biomarker testing for Canadian patients with advanced lung cancer. Melosky B et al. Current oncology (Toronto, Ont.) 2018 Feb 25(1) 73-82 Similar articles in PubMed
FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring BRAF V600E Mutations. Odogwu Lauretta et al. The oncologist 2018 Feb Similar articles in PubMed
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Lindeman Neal I et al. The Journal of molecular diagnostics : JMD 2018 Jan Similar articles in PubMed
Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update. Kalemkerian Gregory P et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018 Feb JCO2017767293 Similar articles in PubMed
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Lindeman Neal I et al. Archives of pathology & laboratory medicine 2018 Jan Similar articles in PubMed
Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy. Osmani Lais et al. Seminars in cancer biology 2017 Nov Similar articles in PubMed
Additional Recommendations for ALK Gene-Rearranged Non-Small-Cell Lung Cancer to the Recently Updated American Society of Clinical Oncology Guideline for Stage IV Non-Small-Cell Lung Cancer. Van Hoef Marlies E H M et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017 Nov JCO2017758367 Similar articles in PubMed
The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016. Tan Daniel S W et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 Jul 11(7) 946-63 Similar articles in PubMed
A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel. Wu Yi-Long et al. ESMO open 2017 2(Suppl 1) e000174 Similar articles in PubMed
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. Hanna Nasser et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017 Aug JCO2017746065 Similar articles in PubMed
Australian recommendations for EGFR T790M testing in advanced non-small cell lung cancer. John Thomas et al. Asia-Pacific journal of clinical oncology 2017 Jul Similar articles in PubMed
Improving molecular testing and personalized medicine in non-small-cell lung cancer in Ontario. Lim C et al. Current oncology (Toronto, Ont.) 2017 Apr 24(2) 103-110 Similar articles in PubMed
ALK-Testing in non-small cell lung cancer (NSCLC): Immunohistochemistry (IHC) and/or fluorescence in-situ Hybridisation (FISH)?: Statement of the Germany Society for Pathology (DGP) and the Working Group Thoracic Oncology (AIO) of the German Cancer Society e.V. (Stellungnahme der Deutschen Gesellschaft für Pathologie und der AG Thorakale Onkologie der Arbeitsgemeinschaft Onkologie/Deutsche Krebsgesellschaft e.V.). von Laffert M et al. Lung cancer (Amsterdam, Netherlands) 2017 Jan 1031-5 Similar articles in PubMed
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. Masters Gregory A et al. J. Clin. Oncol. 2015 Aug 31. Similar articles in PubMed
U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations. Similar articles in PubMed
National Working Group Meeting on ALK diagnostics in lung cancer. Similar articles in PubMed
Guideline Recommendations for Testing of ALK Gene Rearrangement in Lung Cancer: A Proposal of the Korean Cardiopulmonary Pathology Study Group. Similar articles in PubMed
Guideline Recommendations for EGFR Mutation Testing in Lung Cancer: Proposal of the Korean Cardiopulmonary Pathology Study Group. Similar articles in PubMed
Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Similar articles in PubMed